Credit rating agency, CRISIL has reaffirmed AA rating to IPCA Laboratories’ long term bank facilities worth Rs 1182.50 crore. The company has received the rating reaffirmation on the back of its well-diversified business risk profile (across therapeutic segments and geographies), established position in the formulations segment both, in domestic and international market, and integrated operations.
IPCA is one of India’s largest suppliers of bulk drugs, such as atenolol (anti-hypertensive), chloroquine and artemisinin derivatives (anti-malarial), furosemide (diuretic), and pyrantel salts (anthelmintic).
